Details for New Drug Application (NDA): 208984
✉ Email this page to a colleague
The generic ingredient in SELZENTRY is maraviroc. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the maraviroc profile page.
Summary for 208984
Tradename: | SELZENTRY |
Applicant: | Viiv Hlthcare |
Ingredient: | maraviroc |
Patents: | 0 |
Suppliers and Packaging for NDA: 208984
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SELZENTRY | maraviroc | SOLUTION;ORAL | 208984 | NDA | ViiV Healthcare Company | 49702-260 | 49702-260-55 | 1 KIT in 1 CARTON (49702-260-55) * 230 mL in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 20MG/ML | ||||
Approval Date: | Nov 4, 2016 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Oct 30, 2023 | ||||||||
Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
Regulatory Exclusivity Expiration: | Apr 30, 2024 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY |
Expired US Patents for NDA 208984
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | SELZENTRY | maraviroc | SOLUTION;ORAL | 208984-001 | Nov 4, 2016 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription